<?xml version='1.0' encoding='utf8'?>
<text id="AMALGUM_academic_carbamazepine" title="Preparation and Evaluation of Carbamazepine Solid Lipid Nanoparticle for Alleviating Seizure Activity in Pentylenetetrazole-Kindled Mice" shortTitle="carbamazepine" author="Mona Qushawy, Kousalya Prabahar, Mohammed Abd-Alhaseeb, Shady Swidan, Ali Nasr" type="academic" dateCollected="2019-11-03" sourceURL="https://www.mdpi.com/1420-3049/24/21/3971/htm" speakerList="none" speakerCount="0">
<head>
<s type="frag">
1.	LS	1.
Introduction	NN	introduction
</s>
</head>
<p>
<s type="decl">
Epilepsy	NN	epilepsy
is	VBZ	be
a	DT	a
disorder	NN	disorder
in	IN	in
the	DT	the
central	JJ	central
nervous	JJ	nervous
system	NN	system
(	-LRB-	(
CNS	NNP	CNS
)	-RRB-	)
that	WDT	that
is	VBZ	be
characterized	VBN	characterize
by	IN	by
an	DT	a
increase	NN	increase
in	IN	in
the	DT	the
number	NN	number
of	IN	of
electrical	JJ	electrical
impulses	NNS	impulse
that	WDT	that
occurs	VBZ	occur
in	IN	in
one	CD	one
focal	JJ	focal
locus	NN	locus
of	IN	of
the	DT	the
brain	NN	brain
and/or	CC	and/or
the	DT	the
entire	JJ	entire
brain	NN	brain
,	,	,
resulting	VBG	result
in	IN	in
partial	JJ	partial
or	CC	or
generalized	JJ	generalized
seizures	NNS	seizure
.	.	.
</s>
</p>
<p>
<s type="decl">
The	DT	the
administration	NN	administration
of	IN	of
antiepileptic	JJ	antiepileptic
drugs	NNS	drug
is	VBZ	be
mostly	RB	mostly
done	VBN	do
via	IN	via
the	DT	the
oral	JJ	oral
or	CC	or
intravenous	JJ	intravenous
routes	NNS	route
.	.	.
</s>
<s type="decl">
Drug	NN	drug
resistance	NN	resistance
at	IN	at
the	DT	the
late	JJ	late
stage	NN	stage
of	IN	of
therapy	NN	therapy
develops	VBZ	develop
in	IN	in
about	RB	about
40	CD	40
%	NN	%
of	IN	of
patients	NNS	patient
.	.	.
</s>
<s type="decl">
Drug	NN	drug
resistance	NN	resistance
leads	VBZ	lead
to	IN	to
uncontrolled	JJ	uncontrolled
seizures	NNS	seizure
,	,	,
a	DT	a
higher	JJR	high
risk	NN	risk
of	IN	of
brain	NN	brain
damage	NN	damage
,	,	,
and	CC	and
increased	VBN	increase
mortality	NN	mortality
rates	NNS	rate
.	.	.
</s>
<s type="decl">
Patients	NNS	patient
with	IN	with
epilepsy	NN	epilepsy
suffer	VBP	suffer
from	IN	from
emotional	JJ	emotional
and	CC	and
behavioral	JJ	behavioral
changes	NNS	change
,	,	,
seizures	NNS	seizure
,	,	,
convulsions	NNS	convulsion
,	,	,
muscular	JJ	muscular
spasms	NNS	spasm
,	,	,
depression	NN	depression
and	CC	and
,	,	,
in	IN	in
some	DT	some
cases	NNS	case
,	,	,
unconsciousness	NN	unconsciousness
.	.	.
</s>
<s type="decl">
Drugs	NNS	drug
used	VBN	use
for	IN	for
the	DT	the
treatment	NN	treatment
of	IN	of
epilepsy	NN	epilepsy
have	VBP	have
poor	JJ	poor
bioavailability	NN	bioavailability
and	CC	and
eventually	RB	eventually
become	VBP	become
ineffective	JJ	ineffective
over	IN	over
the	DT	the
course	NN	course
of	IN	of
treatment	NN	treatment
due	JJ	due
to	IN	to
drug	NN	drug
resistance	NN	resistance
.	.	.
</s>
</p>
<p>
<s type="decl">
Epilepsy	NN	epilepsy
treatment	NN	treatment
is	VBZ	be
often	RB	often
complicated	VBN	complicate
due	JJ	due
to	IN	to
the	DT	the
poor	JJ	poor
release	NN	release
of	IN	of
the	DT	the
drug	NN	drug
through	IN	through
the	DT	the
adjunctive	JJ	adjunctive
blood	NN	blood
–	SYM	-
brain	NN	brain
barrier	NN	barrier
,	,	,
which	WDT	which
may	MD	may
be	VB	be
overcome	VBN	overcome
by	IN	by
the	DT	the
preparation	NN	preparation
of	IN	of
the	DT	the
drug	NN	drug
as	IN	as
solid	JJ	solid
lipid	NN	lipid
nanoparticles	NNS	nanoparticle
.	.	.
</s>
<s type="decl">
The	DT	the
ideal	JJ	ideal
delivery	NN	delivery
systems	NNS	system
of	IN	of
antiepileptic	JJ	antiepileptic
drugs	NNS	drug
are	VBP	be
the	DT	the
ones	NNS	one
which	WDT	which
provide	VBP	provide
localized	VBN	localize
and	CC	and
controlled	VBN	control
drug	NN	drug
release	NN	release
to	IN	to
targeted	VBN	target
sites	NNS	site
in	IN	in
the	DT	the
brain	NN	brain
,	,	,
which	WDT	which
helps	VBZ	help
to	TO	to
reduce	VB	reduce
drug-associated	JJ	drug-associated
toxicities	NNS	toxicity
and	CC	and
enhances	VBZ	enhance
the	DT	the
efficacy	NN	efficacy
of	IN	of
the	DT	the
drug	NN	drug
.	.	.
</s>
</p>
<p>
<s type="decl">
Carbamazepine	NNP	Carbamazepine
(	-LRB-	(
CBZ	NNP	CBZ
)	-RRB-	)
is	VBZ	be
an	DT	a
antiepileptic	JJ	antiepileptic
drug	NN	drug
with	IN	with
a	DT	a
narrow	JJ	narrow
therapeutic	JJ	therapeutic
index	NN	index
,	,	,
and	CC	and
it	PRP	it
is	VBZ	be
poorly	RB	poorly
absorbed	VBN	absorb
when	WRB	when
taken	VBN	take
by	IN	by
the	DT	the
oral	JJ	oral
route	NN	route
.	.	.
</s>
<s type="decl">
Its	PRP$	its
oral	JJ	oral
bioavailability	NN	bioavailability
is	VBZ	be
75	CD	75
%	NN	%
,	,	,
and	CC	and
its	PRP$	its
maximum	JJ	maximum
achieved	VBN	achieve
plasma	NN	plasma
concentration	NN	concentration
is	VBZ	be
about	RB	about
4	CD	4
–	SYM	-
8	CD	8
h	NN	hour
after	IN	after
administration	NN	administration
.	.	.
</s>
<s type="decl">
Carbamazepine	NN	carbamazepine
acts	VBZ	act
through	IN	through
the	DT	the
inactivation	NN	inactivation
of	IN	of
sodium	NN	sodium
channels	NNS	channel
,	,	,
making	VBG	make
brain	NN	brain
cells	NNS	cell
less	RBR	less
excitable	JJ	excitable
.	.	.
</s>
</p>
<p>
<s type="decl">
Solid	JJ	solid
lipid	NN	lipid
nanoparticles	NNS	nanoparticle
(	-LRB-	(
SLNs	NNS	SLN
)	-RRB-	)
are	VBP	be
considered	VBN	consider
an	DT	a
alternative	NN	alternative
to	IN	to
colloidal	JJ	colloidal
systems	NNS	system
like	IN	like
liposome	NN	liposome
,	,	,
noisome	NN	noisome
and	CC	and
polymeric	JJ	polymeric
nanoparticles	NNS	nanoparticle
.	.	.
</s>
<s type="decl">
SLNs	NNS	SLN
consist	VBP	consist
of	IN	of
solid	JJ	solid
lipids	NNS	lipid
,	,	,
which	WDT	which
act	VBP	act
as	IN	as
a	DT	a
stabilizer	NN	stabilizer
when	WRB	when
dispersed	VBN	disperse
in	IN	in
water	NN	water
in	IN	in
the	DT	the
presence	NN	presence
of	IN	of
a	DT	a
surfactant	NN	surfactant
.	.	.
</s>
</p>
<p>
<s type="decl">
SLN	NNP	SLN
is	VBZ	be
characterized	VBN	characterize
by	IN	by
its	PRP$	its
small	JJ	small
size	NN	size
(	-LRB-	(
nano	NN	nano
range	NN	range
)	-RRB-	)
,	,	,
large	JJ	large
surface	NN	surface
area	NN	area
,	,	,
and	CC	and
high	JJ	high
drug	NN	drug
loading	NN	loading
capacity	NN	capacity
.	.	.
</s>
<s type="decl">
In	IN	in
addition	NN	addition
,	,	,
it	PRP	it
improves	VBZ	improve
drug	NN	drug
stability	NN	stability
and	CC	and
has	VBZ	have
the	DT	the
ability	NN	ability
to	TO	to
improve	VB	improve
the	DT	the
oral	JJ	oral
bioavailability	NN	bioavailability
of	IN	of
poorly	RB	poorly
water-soluble	JJ	water-soluble
drugs	NNS	drug
.	.	.
</s>
<s type="decl">
Gangurde	NNP	Gangurde
and	CC	and
Kumar	NNP	Kumar
prepared	VBD	prepare
lamotrigine	NN	lamotrigine
solid	JJ	solid
lipid	NN	lipid
nanoparticles	NNS	nanoparticle
with	IN	with
a	DT	a
high	JJ	high
efficacy	NN	efficacy
for	IN	for
treatment	NN	treatment
of	IN	of
epilepsy	NN	epilepsy
.	.	.
</s>
<s type="decl">
Nair	NNP	Nair
et	FW	et
al.	FW	al.
prepared	VBD	prepare
carbamazepine	NN	carbamazepine
solid	JJ	solid
lipid	NN	lipid
nanoparticles	NNS	nanoparticle
to	TO	to
improve	VB	improve
its	PRP$	its
therapeutic	JJ	therapeutic
effect	NN	effect
.	.	.
</s>
<s type="decl">
Kumar	NNP	Kumar
et	FW	et
al.	FW	al.
prepared	VBD	prepare
solid	JJ	solid
lipid	NN	lipid
nanoparticles	NNS	nanoparticle
of	IN	of
methylthioadenosine	NN	methylthioadenosine
for	IN	for
the	DT	the
management	NN	management
of	IN	of
neurological	JJ	neurological
conditions	NNS	condition
via	IN	via
oral	JJ	oral
delivery	NN	delivery
.	.	.
</s>
</p>
<p>
<s type="decl">
The	DT	the
objective	NN	objective
of	IN	of
the	DT	the
current	JJ	current
study	NN	study
was	VBD	be
to	TO	to
prepare	VB	prepare
carbamazepine	NN	carbamazepine
solid	JJ	solid
lipid	NN	lipid
nanoparticles	NNS	nanoparticle
(	-LRB-	(
CBZ-SLNs	NNP	CBz-SLNs
)	-RRB-	)
as	IN	as
a	DT	a
novel	JJ	novel
and	CC	and
alternative	JJ	alternative
method	NN	method
for	IN	for
other	JJ	other
colloidal	JJ	colloidal
dispersion	NN	dispersion
carriers	NNS	carry
.	.	.
</s>
<s type="decl">
The	DT	the
study	NN	study
aimed	VBD	aim
to	TO	to
prepare	VB	prepare
CBZ-SLNs	NNPS	CBz-SLNs
with	IN	with
high	JJ	high
entrapment	NN	entrapment
efficiency	NN	efficiency
%	NN	%
,	,	,
small	JJ	small
particle	NN	particle
size	NN	size
,	,	,
and	CC	and
high	JJ	high
anticonvulsant	JJ	anticonvulsant
activity	NN	activity
compared	VBN	compare
to	IN	to
free	JJ	free
CBZ	NNP	CBZ
.	.	.
</s>
</p>
</text>